Ossio, an innovative orthopedic medical device company founded in Israel in 2014, has successfully raised $27.6 million in its latest funding round, marking a significant milestone in its mission to revolutionize orthopedic care. With a focus on transforming the orthopedic experience for physicians, patients, and payors alike, Ossio aims to replace traditional metal implants in the lucrative $10B+ orthopedic fixation market with its cutting-edge OSSIOfiber™ technology. This breakthrough material offers a more biologically friendly alternative, promoting effective bone regeneration while ensuring that nothing permanent is left behind. Unlike conventional implants, Ossio's products are designed to provide the essential mechanical strength for secure fixation and ease of insertion, while simultaneously allowing the body to naturally incorporate and replace the implant as it heals. This innovative approach not only minimizes the adverse inflammation and weakened structures often associated with traditional bio-resorbables but also promotes a streamlined recovery process for patients. The funding will be strategically utilized to accelerate the development and commercialization of Ossio's advanced technologies, allowing them to bring their transformative solutions to the orthopedic market more rapidly. With this significant financial backing, Ossio is poised to enhance patient outcomes and redefine the standard of care in orthopedic surgery, ensuring a future where metal implants are a thing of the past.








